AZN Oct 2024 42.500 put
| Previous Close | 0.2000 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.2300 |
| Strike | 42.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.0800 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksPharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
ZacksAbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
